Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The role of next-generation BTK inhibitors in the treatment of CLL

Matthew Davids • 12 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Pirtobrutinib Venetoclax Zanubrutinib

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the role of next-generation Bruton’s tyrosine kinase (BTK) inhibitors, including acalabrutinib, zanubrutinib, and pirtobrutinib, in the treatment of chronic lymphocytic leukemia (CLL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Matthew Davids

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
1:53
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids • 9 Dec 2023
2:15
CDK9 inhibition with voruciclib for treating AML and R/R B-cell NHL
Matthew Davids • 9 Dec 2023
1:21
Clinical characteristics and outcomes of the double refractory CLL/SLL patient population
Matthew Davids • 9 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals